论文部分内容阅读
NO 18 8 6可以促进脂肪组织、心肌和骨骼肌内脂蛋白酯酶 (lipoproteinlipase ,LPL)mRNA的表达 ,提高其LPL活性 ,从而提高小鼠的肝素后血浆LPL的活性和数量 ;同时NO 1886也能降低血浆甘油三酯 (triglyceride ,TG) ,升高血浆高密度脂蛋白胆固醇 (high densitylipoproteincholestrol,HDL C)水平 ,此外 ,NO 1886还能降低血糖 ,改善胰岛素抵抗和 β 细胞的功能障碍。因此 ,LPL活化剂NO 1886和其他类似激活LPL的制剂对治疗高TG血症、低HDL C水平、预防AS及降低血糖方面有一定的作用
NO 18 8 6 can promote the expression of lipoprotein lipase (LPL) mRNA in adipose tissue, myocardium and skeletal muscle and increase its LPL activity so as to increase the plasma LPL activity and quantity after heparin in mice. Meanwhile, NO 1886 Can lower triglyceride (TG) and increase high density lipoprotein cholesterol (HDL C). In addition, NO 1886 can lower blood glucose, improve insulin resistance and β-cell dysfunction. Thus, the LPL activator NO 1886 and other agents that activate LPL have a role in the treatment of hypercholesteremia, low HDL C levels, prevention of AS and lowering of blood glucose